A5075066985- Viral-associated cancers and disorders
- HIV/AIDS Research and Interventions
- HIV-related health complications and treatments
- HIV Research and Treatment
- HIV, Drug Use, Sexual Risk
- Colorectal Cancer Screening and Detection
- Bladder and Urothelial Cancer Treatments
- Multiple and Secondary Primary Cancers
- Gallbladder and Bile Duct Disorders
- Lymphoma Diagnosis and Treatment
- Pancreatic and Hepatic Oncology Research
- Prostate Cancer Diagnosis and Treatment
- Polyomavirus and related diseases
- Prostate Cancer Treatment and Research
- Diverticular Disease and Complications
- Microscopic Colitis
- Gastric Cancer Management and Outcomes
- Global Cancer Incidence and Screening
- Health Systems, Economic Evaluations, Quality of Life
- HIV/AIDS Impact and Responses
- Economic and Financial Impacts of Cancer
- Cancer Risks and Factors
- Gastrointestinal disorders and treatments
- Genetic factors in colorectal cancer
- Inflammatory Bowel Disease
Mathematica Policy Research
2023-2024
Johns Hopkins University
2014-2024
Restricted mean survival time (RMST) is an underutilized estimand in time-to-event analyses. Herein, we highlight its strengths by comparing to (1) all-cause mortality and (2) initiation of antiretroviral therapy (ART) for HIV-infected persons who inject drugs (PWID) do not drugs. RMST death was determined integrating the Kaplan-Meier curve 5 years follow-up. To account competing risks loss-to-clinic when estimating ART, calculated ART area between cumulative incidence or loss-to-clinic. We...
<h3>Importance</h3> Immunologic decline associated with cancer treatment in people HIV is not well characterized. Quantifying excess mortality treatment–related immunosuppression may help inform guidelines for persons HIV. <h3>Objective</h3> To estimate the association between and CD4 count RNA level posttreatment trajectories all-cause mortality. <h3>Design, Setting, Participants</h3> This observational cohort study included 196 adults who had an incident first available data while care of...
Life expectancy among people with HIV (PWH) is increasing, making chronic conditions-including cancer-increasingly relevant. Among PWH, cancer burden has shifted from AIDS-defining cancers (ADCs) toward non-AIDS-defining (NADCs).
Studies have reported lower incidence of prostate cancer in men living with HIV compared without for reasons that remain unclear. Lower screening could explain these findings. We describe receipt prostate-specific antigen (PSA) test each calendar year by status Medicaid beneficiaries enrolled 14 U.S. states, 2001-2015. A total 15,299,991 aged 18-64 ≥7 months continuous enrollment were included analyses. diagnosis and PSA tests identified using non-drug claims. Incidence rate ratios comparing...
Prostate cancer (PCa) incidence is reportedly lower in men with HIV compared to without for unknown reasons. We describe PCa by status Medicaid beneficiaries, allowing comparison of and who are similar respect socioeconomic characteristics access healthcare. Men (N = 15,167,636) aged 18-64 ≥7 months continuous enrollment during 2001-2015 14 US states were retained analysis. Diagnoses identified using non-drug claims. estimated cause-specific (csHR) comparing status, adjusted age,...
Despite effective antiretroviral therapy (HAART) and durable viral suppression, many HIV-infected individuals still do not achieve CD4 cell count (CD4) normalization. Vitamin D has immunoregulatory functions, including inducing the development of T cells higher levels may improve rebound.Longitudinal study men from Multicenter AIDS Cohort Study who virally suppressed following HAART initiation had pre-HAART post-HAART 25(OH)D 1,25(OH)2D measurements repeated measures CD4.CD4 rebound was...
Background: Studies suggest a lower colorectal cancer (CRC) risk and or similar CRC screening among people with HIV (PWH) compared the general population. We evaluated incidence of endoscopy average-onset (diagnosed at ≥50) early-onset <50) colon by status Medicaid beneficiares comparable sociodemographic factors access to care. Methods: obtained Analytic eXtract (MAX) data from 2001 2015 for 14 states. included 41 727 243 42 062 552 unique individuals least 7 months continuous...
Abstract Background People with human immunodeficiency virus (HIV; PWH) in the United States have a lower incidence of colon cancer than general population. The may be explained by differences receipt screening. Thus, we sought to estimate under scenarios which Medicaid beneficiaries, or without HIV, followed same screening protocols. Methods We used data from 1.5 million beneficiaries who were enrolled 14 US states 2001–2015 and aged 50–64 years; 72 747 had HIV. estimated risks death age,...
Disparities in HIV care by socioeconomic status, place of residence, and race/ethnicity prevent progress toward epidemic control. No study has comprehensively characterized the cascade among people with enrolled Medicaid - an insurance source for low-income individuals US. We analyzed data from 246,127 2001-2015, aged 18-64, living 14 US states. estimated monthly prevalence four steps cascade: retained care/adherent to ART; retained/not adherent; not retained/adherent; adherent....
Prostate cancer is projected to be the most common among people living with HIV; however, incidence of prostate has been reported lower in men HIV compared without little evidence explain this difference. We describe by status Medicaid beneficiaries, allowing for comparison and who are similar respect socioeconomic characteristics access healthcare.
Disparities in HIV care by socioeconomic status, place of residence, and race/ethnicity prevent progress toward epidemic control. No study has comprehensively characterized the cascade among people with enrolled Medicaid - an insurance source for low-income individuals US. We analyzed data from 246,127 2001-2015, aged 18-64, living 14 US states. estimated monthly prevalence four steps cascade: retained care/adherent to ART; retained/not adherent; not retained/adherent; adherent....
Abstract Objective To develop a risk adjustment approach and test reliability validity for oncology survival measures. Data Sources Study Setting We used the National Cancer Institute's Surveillance, Epidemiology, End Results (SEER)‐Medicare data from 2010 to 2013, with mortality through 2015. Design developed 2‐year risk‐standardized rates (RSSR) melanoma, non‐small cell lung cancer (NSCLC), small (SCLC). Patients were attributed group practices based on plurality of visits. identified...
A total of 236 people with HIV (PWH) cancer diagnosed between 1997 and 2014 in the Johns Hopkins Clinical Cohort (JHHCC) were compared a sample from NCI's Surveillance, Epidemiology, End Results (SEER) Program, presumed to be negative. Using G-computation random survival forest methods, we estimated 5-year restricted mean time (RMST) differences by status. Sensitivity analyses performed among non-AIDS defining cancers, males, females, stratifying PWH CD4 ≤ 200 or >200 cells/mm3 at diagnosis....
The inflammatory effects of injection drug use (IDU) may result in an impaired immune response to antiretroviral therapy (ART). We examined CD4 first ART regimen among individuals routine HIV care, stratified by IDU-related acquisition.Cohort study including patients who initiated between 2000 and 2015 the Johns Hopkins Clinic.We followed from initiation until death, loss follow-up, viral load suppression (<500 copies/mL), or administrative censoring. described trajectories after using...
Abstract Background: Colorectal cancer has increased among people living with HIV (PLWH). Studies have reported either no difference or lower risk of colorectal incidence PLWH as compared to the general population. We evaluated colon cancer, both average-onset (diagnosed at 50 older) and early-onset less than 50), a diverse population without who comparable sociodemographic factors access care. Methods: obtained Medicaid Analytic eXtract (MAX) data from 2001-2015 for 14 states. included...
Abstract Background: Studies suggest women living with HIV (WHIV) may have lower breast cancer incidence compared to the general population. To minimize effect of potential differences in prevalence risk factors for and detection between WHIV population, we used data from Medicaid, predominant provider WHIV, compare by status. Methods: We administrative claims aged 18-64 years who were enrolled Medicaid (2001-2009) 14 states (AL, CA, CO, GA, FL, IL, MA, MD, NC, NY, OH, PA, TX, WA), had ≥7...